A phase III trial of ilodecakin [AM0010] in combination with an anti-PD-1 checkpoint inhibitor(pembrolizumab) in patients with solid tumours

Trial Profile

A phase III trial of ilodecakin [AM0010] in combination with an anti-PD-1 checkpoint inhibitor(pembrolizumab) in patients with solid tumours

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Ilodecakin (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Oct 2017 According to an ARMO BioSciences media release, Joseph Leveque, M.D. will lead this trial.
    • 26 Sep 2016 According to an ARMO Biosciences media release, the company anticipates to initiate this study by the end of the year 2016.
    • 26 Sep 2016 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2016, according to an ARMO Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top